Children's Hospital Colorado
Aurora, Colorado, 80045, United States
NCT Number: NCT04407481
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of end-stage kidney disease (ESKD). The disorder is characterized by development and continued growth of multiple cysts requiring renal replacement therapy in 50% of patients by age 60 years. However, ADPKD is also a complex metabolic disorder defined by insulin resistance (IR) and mitochondrial dysfunction which may be causally related to cyst expansion, kidney function decline and contribute to reduced life expectancy. Renal hypoxia, stemming from a potential metabolic mismatch between increased renal energy expenditure and impaired substrate utilization, is proposed as a novel unifying early pathway in the development and expansion of renal cysts in ADPKD. By examining the interplay between renal O2 consumption and energy utilization in young adults with and without ADPKD, the investigators hope to identify novel therapeutic targets to impede development of cyst expansion in future trials.
The investigators propose to address the specific aims in a cross-sectional study with 20 adults with ADPKD (50% female, ages 18-40 years). Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance). For this protocol, participants will complete a one day study visit at Children's Hospital Colorado. Patients will undergo a dual energy x-ray absorptiometry (DXA) to assess body composition, and a 11C-acetate positron emission tomography (PET/CT) scan to quantify renal O2 consumption. After the PET/CT, participants will undergo a hyperinsulinemic-euglycemic clamp while fasting to quantify insulin sensitivity. Glomerular Filtration Rate (GFR) and Effective Renal Plasma Flow (ERPF) will be measured by iohexol and PAH clearances during the hyperinsulinemic-euglycemic clamp.
Looking for future studies?
Notify Me18 year–40 year
All sexes
Observational
Aurora, Colorado, 80045, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Other names: •- Sodium 4-amino hippurate (PAH) inj 20% 2g/10 milliliter (mL) • Para-aminohippurate • Aminohippuric acid
Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Other names: omnipaque 300
Imaging used to visualize the kidneys and quantify renal metabolic activity
Time frame: 30 minutes
11-C Acetate PET/CT
Time frame: 4.5 hours
Hyperinsulinemic-Euglycemic Clamp
Time frame: 5 minutes
Blood draw for mitochondrial DNA copy number
Time frame: 5 minutes
Blood draw for untargeted metabolite assessment of the tricyclic acid (TCA) cycle
Time frame: 5 minutes
Blood draw for targeted assessment and quantification of glucose oxidation using an established metabolite panel
Time frame: 5 minutes
Blood draw for untargeted metabolite assessment of Free Fatty Acid (FFA) oxidation
Time frame: 3 hours
Iohexol Clearance Study
Time frame: 2.5 hours
PAH Clearance Study
Time frame: 5 minutes
Blood draw for Plasma Renin levels
Time frame: 5 minutes
Blood draw for Angiotensin II levels
Time frame: 5 minutes
Blood draw for Copeptin levels
Time frame: 5 minutes
Chitinase-3-like protein 1 (YKL-40) levels
Time frame: 5 minutes
Blood draw for Neutrophil gelatinase-associated lipocalin (NGAL) levels
Time frame: 5 minutes
Blood draw for Kidney Injury Molecule 1 (KIM-1) levels
Time frame: 5 minutes
Blood draw for Interleukin-18 (IL-18) levels
Time frame: 5 minutes
Blood draw for Tumor Necrosis Factor Receptor 1/2 (TNF-R 1/2) levels
Time frame: 5 minutes
Blood draw for monocyte chemoattractant protein-1 (MCP-1) levels
University of Colorado, Denver
Other
PENGUIN: PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD
Acronym: PENGUIN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02847624
Abnormalities, Multiple, Ciliopathies
Tokyo, Japan
View Trial DetailsNCT05521191
ADPKD, Abnormalities, Multiple
Mesa, Arizona, United States
View Trial DetailsNCT04534985
Abnormalities, Multiple, Body Weight
Aurora, Colorado, United States
View Trial DetailsNCT01559363
Abnormalities, Multiple, Ciliopathies
Los Angeles, California, United States
View Trial Details